Diagnostic and health system constraints in pediatric hematologic malignancies in East Africa and implications for WHO classification reconsidering in limited resource settings Authors: Terry Vik, Steven Kussick, Eda Holl, Samuel Boova, Teresa Lotodo, Nicholas Kigen, Tyler Severance, LaToya Montgomery Published: 2026 ABSTRACT AbstractPurpose of the reviewPediatric hematologic malignancies, particularly leukemia and lymphoma, represent a major and growing contributor to childhood cancer mortality in low- and middle-income countries (LMICs). In sub-Saharan Africa, more than 100,000 children develop cancer annually, with survival rates estimated at 20–30%, compared with over 80% in high-income countries, largely due to delayed diagnosis and limited access to specialized care. This narrative and conceptual review, informed by prior empirical work conducted in Kenya and Uganda, examines challenges in implementing World Health Organization (WHO) hematologic malignancy classification frameworks in pediatric care settings in East Africa. Specifically, our research has revealed that cancer classification in this region, beyond the conventional binary of benign versus malignant status for the relevant clinical sample, in many instances requires relatively high-cost technologies that are not available and/or not affordable for non-affluent patients, thus precluding definitive WHO classification of many hematolymphoid malignancies. From our perspective, the significant challenges to applying the verbatim WHO classification in LMICs, for both hematolymphoid and non-hematolymphoid malignancies, underscores the immediate need for an alternative, somewhat simpler classification system designed to evolve in its complexity as increasing resources for both diagnosing and treating cancer reach in LMICs.Prior findingsAlthough approximately 85% of African countries are geographically located within the sub-Saharan region, cancer fatality rates continue to rise, particularly in LMICs. In addition to cancer, populations in these regions are burdened by high prevalence rates of human immunodeficiency virus (HIV)/Acquired Immunodeficiency Syndrome (AIDS) and various chronic diseases. Our earlier research, conducted at Kenya’s Moi Teaching and Referral Hospital and Uganda’s Ministry of Health National Laboratory Diagnostic Services, revealed a significant number of pediatric patients suffering from hematological conditions, most notably leukemia and lymphoma. Despite presenting with clear signs and symptoms of these malignancies, many children lacked access to affordable and reliable diagnostic screening tools. As a result, children with presumptive cases of cancer often faced considerable barriers, including long-distance travel and costly diagnostic procedures such as flow cytometry and immunohistochemistry. These tests are not covered by the region’s National Health Insurance Fund (NHIF), placing additional financial strain on families. Compounding these challenges are systemic issues such as limited staffing, supply shortages, and outdated diagnostic equipment lacking technical support. Collectively, these factors contribute to delayed or ineffective treatment and ultimately lower patient survival rates. In sub-Saharan Africa, rising cancer mortality occurs in the context of overlapping health-system challenges, including a high burden of infectious diseases such as HIV/AIDS alongside growing rates of noncommunicable diseases. Although Africa represents a smaller share of the global cancer burden, limitations in diagnostic capacity and cancer surveillance contribute to under recognition of many malignancies, particularly pediatric hematologic diseases. In our previous work at Moi Teaching and Referral Hospital in Kenya and within Uganda’s Ministry of Health National Laboratory Diagnostic Services, we observed a substantial number of children presenting with suspected leukemia and lymphoma. Many of these patients exhibited advanced clinical features at presentation but lacked access to essential diagnostic tests necessary for accurate classification and risk stratification. Flow cytometry and immunohistochemistry were frequently unavailable or unaffordable, requiring long-distance travel and imposing significant financial strain on families. Additional barriers—including shortages of trained laboratory personnel, limited technical support, supply chain interruptions, and aging diagnostic equipment—further hindered timely diagnosis and appropriate disease classification. These findings underscore the gap between existing WHO classification frameworks and their practical implementation in pediatric care settings in East Africa.SummaryThe primary challenge in pediatric hematologic malignancy care in East Africa is not the conceptual adequacy of WHO classification systems, but much rather the need for a more accessible and adaptable classification framework that evolves with diagnostic capacity, particularly in LMICs where such resources are limited. Investing in strengthened diagnostic capabilities and clinical resources are essential for achieving equitable implementation, especially with leukemia and lymphoma testing within such areas. Sustained investments of this nature are needed to combat disparities and improve pediatric cancer outcomes in disease classification and tailored therapies.Keywords: Challenges, WHO classification, Leukemia, Diagnostics, East Africa Introduction Hematologic malignancies constitute a growing public health concern in sub-Saharan Africa, where cancer mortality continues to rise amid constrained health system capacity [1–6]. In 2020, an estimated 520,000 cancer-related deaths occurred in the region, and annual cancer mortality is expected to increase to approximately 1.4 million deaths by 2040, driven largely by population growth and aging [7–9]. Despite accounting for a smaller proportion of the global cancer burden, countries in this region experience disproportionately high mortality-to-incidence ratios, reflecting delayed diagnosis, limited access to care, and incomplete disease classification. These challenges are particularly pronounced in pediatric populations, where leukemias and lymphomas represent some of the most common and treatable childhood cancers, yet are frequently diagnosed late or not classified according to recommended standards. Advances in flow cytometry, along with immunohistochemistry, cytogenetics, and molecular diagnostics, have significantly improved the diagnosis, classification, and risk stratification of hematologic malignancies, particularly in pediatric populations [10–12]. Flow cytometry remains a cornerstone of leukemia and lymphoma diagnosis, enabling rapid lineage assignment and immunophenotypic characterization that directly informs classification and treatment decisions [10–12]. Contemporary World Health Organization (WHO) and International Consensus Classification (ICC) frameworks build upon these diagnostic modalities by integrating morphologic, immunophenotypic, genetic, and clinical features to define disease entities with increasing precision [13–15]. However, the effective implementation of these classification frameworks is highly dependent on access to essential diagnostic technologies and trained laboratory personnel. In many low-resource pediatric care settings, recommended tools such as flow cytometry and immunohistochemistry are limited, inconsistently available, or financially inaccessible, restricting the ability to fully apply WHO-aligned diagnostic pathways [1, 13]. Consequently, children with suspected leukemia or lymphoma may undergo incomplete diagnostic evaluation, experience delays in classification, or receive empiric treatment without full risk stratification. These challenges reflect barriers to implementation rather than limitations of the WHO or ICC classification systems themselves [13–18]. Our previous work conducted at Kenya’s Moi Teaching and Referral Hospital and in collaboration with Uganda’s Ministry of Health National Laboratory Diagnostic Services revealed a substantial number of pediatric patients affected by hematologic conditions, most notably leukemia and lymphoma [16, 17]. Many children presented with clear clinical signs and symptoms of malignancy; however, access to affordable and reliable diagnostic screening tools remained limited. As a result, presumptive cases often encountered significant barriers to diagnosis, including long-distance travel and the high cost of essential diagnostic procedures such as flow cytometry and immunohistochemistry, which are frequently not covered by national health insurance programs. These challenges were further compounded by systemic constraints, including limited trained personnel, supply shortages, and outdated laboratory infrastructure with minimal technical support. Collectively, these factors contributed to delayed diagnosis, incomplete disease characterization, and suboptimal treatment initiation. Drawing on these experiences, this review examines challenges encountered in pediatric hematologic malignancy diagnosis and classification in East Africa, with particular attention to how resource limitations affect the practical application of internationally recommended diagnostic and classification approaches. Current knowledge Malignancies Within oncology, countless hematological malignancies exist and are classified into various subtypes, consisting of leukemia, multiple myeloma, and lymphoma (non-Hodgkin lymphoma and Hodgkin lymphoma); hence, being denoted as some of the most prevalent cancer types with increased global incidence, excessive mortality rates, and complicated healthcare challenges [19, 20]. As part of the 2022 Global Cancer Observatory (GLOBOCAN), the actual number of leukemias, multiple-myelomas, non-Hodgkin lymphomas, and Hodgkin lymphomas tended to exceed 1.3 million [20]. While the most current WHO 5th edition [21] demonstrated significant hematolymphoid malignancy classification updates, emphasizing lineage-defining markers, fusion-driven subtypes, and rare entities, our prior research resulted in creating a diagnostic immunophenotyping reference chart specifying disease categories, color-coded diagnostic markers, and unique phenotypes for better leukemia diagnosis and cross referencing within practical or real-world settings (Fig. 1). Immunophenotyping Reference Table (WHO Classification of Tumours Editorial Board. Haematolymphoid tumors. WHO Classification of Tumours series, 5th edition, volume 11 [Internet; beta version ahead of print]. Lyon (France): International Agency for Research on Cancer; 2022 Accessed November 12, 2025. Available from: https://tumourclassification.iarc.who.int/chapters/63) [22] Recent advances in therapeutic treatment An array of emerging technologies exists for detecting clinically important diagnostic, prognostic, and predictive markers of hematological malignancy [23]. While conventional therapies (surgery, radiotherapy, and chemotherapy) have resulted in more cancer survivors, continual disease progression, relapses, and cancer recurrences tend to occur in an increased number of patients [24, 25]. For these patients, recent advances, such as adoptive cell therapies (ACTs), provide advantageous benefits utilizing “live” drugs, allowing the patient’s immune cells to be subject to in vitro collection, processing, and engineering while the cells are reinfused back into the patient’s body to help eliminate cancer cells [25]. Adoptive cell therapies offer an alternate route utilizing chimeric antigen receptor (CAR) modified T cells, tumor-infiltrating lymphocytes (TILs), or T cell receptor (TCR) gene therapy with several modes of action [24]. Of the three routes, the CAR modified T cell approach provides better therapeutic outcomes because it adjusts the tumor microenvironment (TME) with CAR expression T cell induction into patient’s T cells by ex vivo or in vivo procedures to accurately identify as well as destroy the cancer cells [26]. Alternative approaches to ACTs are natural killer (NK) cells and NK-based ACT therapies [27]. Natural killer cells cells aid in cancer defense by directly killing, releasing cytokines, and stimulating antibody-dependent cell-mediated cytotoxicity (ADCC) with major CD 16 binding to the Fc antibody region. In addition, NK cells have abilities to demonstrate CAR dependent targeting specificity and prohibit antigen release while returning to their original state. Cumulatively, this strategy is advantageous due to its clinical safety and anti-tumor benefits [27]. Generating a personalized or individualized precision medicine (PM) approach employing a cellular product with tumor specificity is the overall aim for malignant ACTs. In general, individualized strategies tend to be essential concepts with cancer treatment in measurable/minimal residual disease (MRD) since small residual tumor cell numbers can result in disease relapse [23]. Amongst acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndromes, and other hematological diagnoses, MRD measurement has become a pivotal tool for risk stratification and therapeutic decision making, as it offers a more precise and sensitive means for patient disease monitoring as well as patient response to therapy in comparison to traditional approaches. However, a synergistic relationship must exist between the patient’s immune system and comprehensive treatment efficacy [28]. In our study, we analyzed both peripheral blood samples and bone marrow aspirates for all patients. The study methodology consisted of Beckman Coulter’s comprehensive 4-tube CLearLLab 10 C assay and the 10-color/12-parameter LS screening tube. While a single LS tube and the 4-tube CLearLLab 10 assay were used for comparative flow cytometry analysis, an LS screening tube method was also applicable for the analysis. Key challenges Inability for further leukemia classification Hematological malignancy classification and diagnosis are both essential entities for effective cancer management [13]. While hematological malignancies present with diverse clinical symptoms and outcomes, current classification and diagnoses tend to be based on the most recent WHO and ICC editions, which include guideline data provided within high-resource countries [13–15]. More importantly, several traditional technologies, such as chromosomal banding analysis, fluorescence in situ hybridization (FISH), genomic arrays, and Sanger sequencing are utilized for identifying essential genetic abnormalities during diagnosis [23]. Although MRD measurement provides prognostic risk stratification and guides treatment decisions, these measurements also require specialized laboratory tests and well-standardized technologies, namely multiparameter flow cytometry, quantitative polymerase chain reaction (PCR), droplet digital PCR (ddPCR), and next generation sequencing molecular diagnostic procedures. During our research, we found that diagnostic resources were unavailable for further leukemia classification in many of the pediatric cases. For example, materials for optimal tissue processing as well as glade slide-based testing essentials were unobtainable. In addition, specialized diagnostic procedures such as immunohistochemistry and FISH were also out of reach. Existing research supports our stance revealing that the limited availability of specialized diagnostic techniques and a lack of accurate cancer population register data are important challenges, especially in LMICs [1, 13]. Lack of trained professionals and laboratory personnel Another significant barrier to appropriate oncology control in LMICs pertains to the shortage or lack of sufficient trained cancer professionals for laboratory diagnostics and the overall workforce [29]. In comparison to economically advantaged countries, LMICs have significantly more caseloads and clinical tasks as well as increased shortages of diagnostic specialists (pathologists, oncologists, radiologists). Additionally, the lack of adequate oncology training programs failing to prioritize cancer management during medical school education creates difficulties with instructing and retaining cancer healthcare professionals within these settings [30]. Similarly, we observed limited trained professionals within our study regions. For those reasons, our prior work implemented training via a multi-modal educational program utilizing the Project Extension for Community Healthcare Outcomes model [17]. Under this training program, participants included both clinical and laboratory personnel (pathologists, laboratory scientists, hematologists, and medical officials) while qualitative and quantitative components were applied for flow cytometry learning competencies as well as for overall pediatric leukemia diagnostic comprehension. Sustainability and reimbursement issues Global sustainability requires a two-fold approach encompassing the adoption of pro-sustainable activities in addition to supporting and eliminating actions that impact the ecosystem unfavorably [31]. Although sustainability involves important safety environmental actions, addressing climate change tends to be one of the most critical aspects of sustainability. Unfortunately, healthcare is one of the most contributing factors to climate change due to enormous energy and resource consumption. Despite minimal climate change contributions by LMICs, they tend to lack adequate resources to handle the condition effectively [32]. Factors responsible for sustainability issues include outdated equipment, inadequate clean energy, and heighted patient travel to access services, which all result in significant contributions to the overall carbon footprint [32]. In a clinical trial study by Eldridge, respondents noted that financial challenges ranked highest in LMICs, including inappropriate salaries and limited personnel funding [33]. While respondents voiced that prior funding processes did not allow reimbursement or advance personnel payments, they also expressed concern for poor salaries and funding for personnel. Although patients within our study region faced reimbursement issues, we offered flow cytometry testing at no cost to the families of pediatric patients as a direct benefit of the study. Since next generation high parameter flow cytometry with 3 lasers can detect up to 13 colors using avalanche photodiode detectors, offering high sensitivity and accuracy, it was also provided for the study. The next generation technology applies wavelength division multiplexer that increases light efficiency, where light loss is minimized by refraction. These advanced technologies are more reliable, less costly to maintain, and more energy efficient compared to conventional outdated equipment within the lower-resource settings. In our research, we found that both sustainability and reimbursement difficulties served as additional hurdles within East Africa, particularly Kenya and Uganda. Our data demonstrated that most sustainability issues were related to a lack of renewable energy, outdated equipment, and increased patient travel to access services. Most of the reimbursement issues pertained to no coverage for medical or diagnostic procedures by the LMICs representative insurance agencies, resulting in more out-of-pocket expenses for the parents or caretakers of pediatric patients within these low-resource settings. Supply chain and regulatory hurdles Despite the unstructured medical distribution system in most LMICs, supply chain management serves as an important entity for ensuring that reagents, supplies, and pharmaceutical distributions comply with temperature guidelines for product quality and integrity [34]. A technology known as Dura Innovations circumvents the need for cold chain and inventory supply of liquid antibodies used for lab developed tests that are difficult to source. Dura Innovations provides dry, unitized reagents pre-mixed for accurate immunophenotyping. This innovation for pre-mixed tests eliminates cold chain concerns, quality, stability, and costly inventories of antibodies needed to assemble a lab developed test. Chukwu and his team examined the quality of practice for the supply chain management of cold products and discovered that there were several issues [34]. Some of these obstacles included failed quality standards for storage facilities, poor pharmacy facility practices, uncalibrated equipment, no back-up system alternatives for power failures, and temperature check omissions for products upon supplier receipt. Similarly, weak regulatory guidelines present challenges for LMICs as well. According to a 2017 WHO report, ineffective regulations in LMICs are responsible for the distribution of 1 in 10 substandard or false (SF) medical products, resulting in adverse health outcomes, treatment failure, drug resistance, and decreased trust in the healthcare system [35]. Overall data demonstrated that people residing within African countries generally receive SF medicines from nearly every pharmacy and experience negative or fatal adverse outcomes. The WHO is making efforts to address the reliance and quality regulation of medical products in Africa and other LMICs. The WHO introduced the Global Benchmarking Tool (GBT) to allow for the assessment of a country to become a WHO Listed Authority. The GBT establishes a framework for countries to meet criteria at various maturity levels to become a stringent regulatory authority. The purpose is to develop a quality management process with reliance on safe, effective and quality medical products that ensure good regulatory practices. The GBT framework categorizes countries at Maturity Level (ML) 1–4. Maturity Level 1 is regulatory authority in a country with no formal approach for regulation of medical products, ML 2 means there is an evolving national regulatory system that partially performs essential regulatory function, ML 3 means there is a stable well-functioning regulatory system, and ML 4 is an advanced regulatory system with continuous improvement [36]. According to Broojerdi et al., most countries in Africa are ML1 with approximately 20% ML 3 and 4 [36]. Our data has also shown that both supply chain and regulatory challenges remain ongoing. We have noticed limited availability with supply chain transport, monitoring, and management. For our study, sample transport to MTRH was extremely difficult. In addition, the transport delays had potential to affect sample quality and integrity, making the sample unsuitable for hematological testing upon arrival. Issues of this nature resulted in even more hurdles because some pediatric samples were incapable of being redrawn for testing during the specified time frame. These difficulties also affected the pediatric study population and total regulatory compliance for sample and reagent processing procedures. Financial toxicity preventing access to care In LMICs, many patients undergoing oncology treatment experience financial toxicity, the likely consequence of perceived subjective economic financial distress [37, 38]. The elevated costs associated with malignancy treatment include increased insurance costs with overpriced co-payments and costly deductibles, resulting in extreme out of pocket expenses [38]. In addition to these roadblocks, pediatric patients in our representative settings as well as in LMICs also experience suboptimal access to treatment or proper therapeutic care [1, 13, 18]. While Eldrige and his researchers affirmed that oncology clinical trials are beneficial for developing new standards of care and testing the safety of cancer drugs, they also exclaimed that patients were presented with problems of traveling far distances to access care in cancer facilities [33]. Although many of the patients require transportation and accommodation assistance, these types of services are not supported by clinical trials and the funding agencies. In our study, we had an opportunity to witness financial toxicity preventing pediatric access to care first-hand. In most cases, adequate transport was either non-existent or very costly, resulting in parents bicycling or walking long distances with their children for medical care and diagnostic procedures. In addition to traveling difficulties, we also observed patients making tough financial decisions related to proper care. For example, patients experienced severe stress when having to choose between feeding their families or having a diagnostic medical procedure due to their conditions. Collectively, patients experienced financial toxicities related to personal financial constraints as well as from mistrust of officials making poor financial decisions and the entire healthcare system in general. Discussion In this review, we describe our work with pediatric leukemia and lymphoma patients in low-resource settings in East Africa and place these experiences within the broader context of advances in hematologic malignancy diagnostics. While substantial progress has been made globally in the classification and treatment of hematologic malignancies, these advances have not been equitably realized across all settings. Our observations from Kenya and Uganda underscore the persistent gap between diagnostic standards recommended in international guidelines and the realities of clinical practice in many low- and middle-income countries. The challenges observed in our work—limited access to flow cytometry and immunohistochemistry, shortages of trained personnel, infrastructure constraints, and financial barriers—primarily reflect system-level shortcomings and implementation limitations rather than intrinsic deficiencies in existing disease classification frameworks. Contemporary WHO and ICC classification systems are comprehensive and multidimensional; however, their effective application depends on the availability of diagnostic modalities that remain inaccessible to many pediatric patients in low-resource settings. As a result, children with suspected hematologic malignancies may experience delayed diagnosis, incomplete classification, or empiric treatment decisions that are not fully risk-adapted. Importantly, these findings should not be interpreted as evidence that new or alternative global classification systems are required. Rather, they highlight the need to strengthen diagnostic capacity and structural limitations within the healthcare infrastructure to support equitable implementation of existing classification frameworks. Without such investments, advances in disease classification and PM risk widening, rather than narrowing, disparities in pediatric cancer outcomes. Limitations Due to the global perspective of this review, only pediatric patients from a few low resource entities were assessed, meaning that this study may restrict applicability to other resource scarce regions. In addition, a degree of variability is possible with some areas demonstrating better representation than other areas or to some extent no representation at all. While this review has focused on several essential challenges in Kenya and Uganda, other well-documented barriers may not be represented. Results of this review may also be influenced by sample quality variability, transportation logistics, and educational training constraints for health clinicians and professionals. Nevertheless, findings from this review will provide more direction for combatting challenges in East Africa and further insight regarding pediatric hematolymphoid disease classification; however, these findings from several single areas may limit generalizability to additional low-resource limited countries within sub-Saharan Africa and beyond. Conclusion In LMICs like Africa, several obstacles affect assess to care and equitable healthcare. For pediatric hematologic malignancy care in East Africa, the essential challenge is not the conceptual adequacy of WHO classification systems, but inequitable implementation resulting from these obstacles (diagnostic, financial, and health-system constraints). Efforts to correct these hurdles are improving with more advances towards pediatric hematologic malignancy diagnostics, especially leukemia and lymphoma testing. As such, the former WHO classification system and its applicability will more than likely continue to rely on access to diagnostic approaches which are not readily available to the pediatric population in East Africa as well as additional resource-limited areas. Moreover, any developmental advances or upgrades will benefit diagnostic testing and improve outcomes for pediatric patients suffering from hematologic malignancies in LMICs as well as within the surrounding area. Author contributions “T.V., S.K., E.H., S.B., T.L., N.K., T.S., and L.M. contributed with a group effort in the drafting or conceptual design of the main manuscript text. T.V., S.K., E. H., and T.B. prepared figure 1. T.V., S.K., N.K., T.L., and T.S. contributed with data analysis and interpretation. All authors reviewed the manuscript.” Funding Financial support for this work was provided via funding from the National Cancer Institute. None of the funders played a role in manuscript review preparation, data collection and analysis, interpretation, or writing of the review article. Data availability. Not applicable. Data availability No datasets were generated or analysed during the current study. Declarations Ethics approval and consent to participate Not applicable. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement No datasets were generated or analysed during the current study.